Evaxion Biotech (EVAX) has released an update. Evaxion Biotech, a clinical-stage company leveraging its AI-Immunology platform to create innovative vaccines, is set to announce its Q3 2024 ...

COPENHAGEN, Denmark, December 9, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines ...

Evaxion Biotech (NASDAQ:EVAX) just reported results for the first quarter of 2024. Evaxion Biotech reported earnings per share of 3 cents. This was above the analyst estimate for EPS of -56 cents ...

As anticipated, Evaxion has received a delisting determination The determination has been appealed by Evaxion requesting a hearing on the matter and seeking another 180-day extension to comply ...

Evaxion Biotech (EVAX) will present preclinical Proof-of-Concept for its precision cancer vaccine concept, targeting non-conventional ERV tumor antigens shared across patients at the ESMO Immuno ...